Get the Stockscreener App
0.4202
8.65%
-0.0398
Silexion Therapeutics Corp stock is traded at $0.4202, with a volume of 997.15K.
It is down -8.65% in the last 24 hours and down -83.19% over the past month.
Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for cancers driven by mutations in the mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS). Its proprietary technology is designed to prompt tumor cells to degrade the messenger RNA (mRNA) that bridges the oncogene and the cellular protein synthesis machinery, utilizing small interfering RNA (siRNA) constructs that are chemically modified to enhance stability and cellular uptake while maintaining biological activity that interferes with the mRNA function. Its product candidate, SIL204, is a second-generation siRNA engineered to suppress the production of mutated KRAS proteins.
See More
Previous Close:
$0.46
Open:
$0.4143
24h Volume:
997.15K
Relative Volume:
1.36
Market Cap:
$446.72K
Revenue:
-
Net Income/Loss:
$-12.91M
P/E Ratio:
-0.00444
EPS:
-94.5617
Net Cash Flow:
$-12.02M
1W Performance:
-77.53%
1M Performance:
-83.19%
6M Performance:
-97.36%
1Y Performance:
-99.43%
1-Day Range:
$0.373
$0.4202
1-Week Range:
$0.373
$1.8439
52-Week Range:
$0.373
$80.00
Silexion Therapeutics Corp Stock (SLXN) Company Profile
Name
Silexion Therapeutics Corp
Sector
Industry
Phone
972-8-6286005
Address
12 ABBA HILLEL ROAD, RAMAT GAN
Compare SLXN vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLXN
Silexion Therapeutics Corp
|
0.4202 | 482.76K | 0 | -12.91M | -12.02M | -94.56 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Silexion Therapeutics Corp Stock (SLXN) Latest News
Silexion Therapeutics (SLXN) seeks huge share boost and reverse split to stay on Nasdaq - Stock Titan
Silexion Q2 EPS $(5.17) misses $(2.12) estimate; loss widens - scanx.trade
Silexion Therapeutics Raises $35 Million in August Public Offering - Minichart
Silexion Therapeutics Corp 2Q 2026: Net loss $3.55M, EPS $(12.41) — 10-Q Summary - TradingView
Silexion Initiates Phase 2/3 Pancreatic Cancer Trial on July 29 - Minichart
Silexion Therapeutics Reports Second Quarter 2026 Financial Results And Provides Business Update - TradingView
Silexion Reports $3.6 Million Second-Quarter Net Loss as SIL204 Trial Starts - quiverquant.com
Silexion Therapeutics reports Q2 2026: $3.6M Q2 net loss, $2.2M cash at June 30 - TradingView
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - Yahoo! Finance Canada
Silexion Completes 1-for-10 Reverse Share Split - Minichart
Top Silexion Therapeutics CorpWarrant (SLXNW) Competitors 2026 - MarketBeat
Form 8K Silexion Therapeutics Corp For: 13 August By Investing.com - Investing.com Nigeria
Silexion Therapeutics Executes Reverse Share Split Amid Strain - TipRanks
Silexion Therapeutics Closes Public Offering and Strengthens Equity - TipRanks
Silexion Therapeutics Corp (SLXN) investors report 0% holding but retain warrants - Stock Titan
Silexion Therapeutics Corp SEC Filing (Aug 12, 2026) - Stock Titan
Silexion Therapeutics Prices $2.5 Million Securities Offering; Shares Down Pre-Bell - marketscreener.com
Silexion prices $2.5M offering to fund KRAS cancer trial - Dealroom
Silexion Therapeutics prices $2.5M public offering at $0.65 By Investing.com - Investing.com Nigeria
Silexion Therapeutics prices $2.5M public offering at $0.65 - Investing.com
Silexion Intends to Use Offering Proceeds for Pancreatic Trial - Stock Titan
Silexion Therapeutics Prices $2.5 Million Public Offering of Ordinary Shares and Warrants - Quiver Quantitative
Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering - GlobeNewswire
Immunotherapy’s Biggest Blind Spot Is a $7 Billion Market. Silexion May Have a Way In (NASDAQ: SLXN) - TipRanks
Immunotherapy's Biggest Blind Spot Is a $7 Billion Market. Silexion May Have a Way In (NASDAQ: SLXN) - Benzinga
Immunotherapy's Biggest Blind Spot Is A $7 Billion Market. Silexion May Have A Way In (NASDAQ: SLXN) - Menafn
Form 8K Silexion Therapeutics Corp For: 10 August By Investing.com - Investing.com Nigeria
Silexion Updates SIL204 Clinical and Regulatory Roadmap - TipRanks
Silexion Therapeutics (SLXN US): Synthetic Expert Call Transcript (10 Aug 2026) - Smartkarma
Silexion Therapeutics publishes corporate deck spotlighting SIL204 siRNA program targeting KRAS-driven cancers - Bitget
Maxim Group Maintains Silexion Therapeutics(SLXN.US) With Hold Rating - 富途牛牛
IPO Databook: Silexion Therapeutics (SLXN US)Aug 2026 - Smartkarma
Silexion Therapeutics (NASDAQ: SLXN) files S-1 for best-efforts unit sale - Stock Titan
Silexion unveils key SIL204 KRAS preclinical findings - TipRanks
Silexion to present preclinical data on SIL-204 at GI cancer event - Investing.com
Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers - The Manila Times
Silexion Therapeutics Reports Preclinical Data Showing SIL204 Immune-Sensitizing Effects in KRAS-Mutant Cancer Cells - Quiver Quantitative
Silexion's SIL204 Alters Three Immune Pathways in Cancer Cells - Stock Titan
Silexion Therapeutics Restores Nasdaq Audit Committee Compliance - TipRanks
Silexion Therapeutics restores Nasdaq audit committee compliance with new appointment - TradingView
Silexion Therapeutics Announces Board Member Resignation - TipRanks
Silexion Therapeutics Warrant (SLXNW) Holds at $0.02 as Range-Bound Trading PersistsVolatility Stop - dars.gov.et
Biomotion Sciences Ordinary Shares (NASDAQ: SLXN) Stock Price, News & Analysis - Kalkine
Amnon Peled resigns from Silexion Therapeutics board effective Aug 1, 2026 - TradingView
Maxim Downgrades Silexion Therapeutics to Hold From Buy - marketscreener.com
Silexion Therapeutics Corp Warrant (SLXNW) Holds Near Par After Modest DeclineHead and Shoulders - dars.gov.et
Silexion Begins Phase 2/3 Trial in Pancreatic Cancer - TipRanks
Silexion Activates First Site in Phase 2/3 Trial Targeting KRAS-Driven Pancreatic Cancer (NASDAQ: SLXN) - tipranks.com
Silexion Therapeutics Successfully Initiates Phase 2/3 - GlobeNewswire
Silexion Therapeutics Initiates Phase 2/3 Trial for Pancreatic Cancer Drug Candidate - Moomoo
Silexion Activates First Site In Phase 2/3 Trial Targeting KRAS-Driven Pancreatic Cancer (NASDAQ: SLXN) - Menafn
Silexion Therapeutics Corp Stock (SLXN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):